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Abstract
Background: Neuropsychiatric disorders are common forms of disability in humans. Despite recent progress in
deciphering the genetics of these disorders, their phenotypic complexity continues to be a major challenge.
Mendelian neuropsychiatric disorders are rare but their study has the potential to unravel novel mechanisms that
are relevant to their complex counterparts.
Results: In an extended consanguineous family, we identified a novel neuropsychiatric phenotype characterized by
severe speech impairment, variable expressivity of attention deficit hyperactivity disorder (ADHD), and motor delay.
We identified the disease locus through linkage analysis on 15q21.2, and exome sequencing revealed a novel
missense variant in GNB5. GNB5 encodes an atypical β subunit of the heterotrimeric GTP-binding proteins (Gβ5).
Gβ5 is enriched in the central nervous system where it forms constitutive complexes with members of the
regulator of G protein signaling family of proteins to modulate neurotransmitter signaling that affects a number of
neurobehavioral outcomes. Here, we show that the S81L mutant form of Gβ5 has significantly impaired activity in
terminating responses that are elicited by dopamine.
Conclusions: We demonstrate that these deficits originate from the impaired expression of the mutant Gβ5
protein, resulting in the decreased ability to stabilize regulator of G protein signaling complexes. Our data suggest
that this novel neuropsychiatric phenotype is the human equivalent of Gnb5 deficiency in mice, which manifest
motor deficits and hyperactivity, and highlight a critical role of Gβ5 in normal behavior as well as language and
motor development in humans.
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Background
It is increasingly recognized that neuropsychiatric disorders
have complex etiology and that many conditions defy clas-
sical definitions based purely on phenotypic observations
[1]. While there has been tremendous progress towards un-
derstanding the genetic basis of hereditary neuropsychiatric
conditions, linking specific pathological states to exact mo-
lecular alterations has been challenging [2].
One large group of genes with prominent roles in neuro-
psychiatric disease process encodes components of neuro-
transmitter signaling cascades acting via G protein coupled
receptors (GPCR) [3]. Notably, pharmacological modula-
tion of signaling efficacy at GPCR has been among the
most successful strategies for controlling the symptoms of
several mental conditions [4]. In the context of neurodeve-
lopmental disorders manifesting in hyperactivity, this fre-
quently includes modulation of signaling via receptors for
neurotransmitter dopamine [5]. GPCRs transmit their sig-
nals by activating heterotrimeric guanine nucleotide-
binding proteins (G proteins). In the basal state, the GDP-
bound Gα subunit is tightly bound to the Gβγ heterodi-
mer. Upon successful binding of GPCRs to their ligands,
GDP is exchanged for GTP and the heterodimer dissoci-
ates such that each of its components can initiate a series
of signaling cascades that mediate the net biological effect
of the ligand [6].
The strength of the signaling in GPCR cascades is con-
trolled by the members of the regulator of G protein sig-
naling (RGS) proteins, which terminate the signaling
initiated by the GPCRs by accelerating the GTP hydroly-
sis on the Gα subunits, thereby promoting their inactiva-
tion. RGS proteins also act as signaling thresholders
preventing constitutive and uncontrolled G protein signal-
ing in the absence of GPCR activation [7–11]. In the ner-
vous system, the critical role in controlling GPCR
signaling belongs to members of the R7 subfamily of RGS
proteins that includes RGS6, RGS7, RGS9, and RGS11.
Collectively, R7 RGS proteins have been implicated in
learning, motor control, and vision by controlling several
neurotransmitter systems including dopamine, opioid,
glutamate, and GABA [12]. However, with an exception of
the established role of RGS9 in retina pathology [13] and
ample evidence from mouse models [14], contributions of
R7 RGS proteins to inherited neuropsychiatric conditions
in humans has not been documented, despite their stra-
tegic role in controlling key relevant processes.
A hallmark of R7 RGS protein organization is their as-
sociation with Gβ5, a divergent member of the Gβ fam-
ily through their Gγ-like (GGL) domains [15–17]. Gβ5 is
encoded by GNB5 and shares only ~50 % sequence simi-
larity with classical Gβ1–4 subunits that transmit GPCR
signals and are ~90 % identical to each other. Gβ5 also
appears to be the only member of Gβ family that can
have cellular localization other than the cell membrane,
e.g. cytosolic and nuclear [18]. All R7 RGS proteins in
vivo exist in complexes with Gβ5, and Gβ5 together with
its R7 RGS partners depend on each other for stability;
in addition, the GTPase activating protein (GAP) activity
of R7 RGS proteins is enhanced several folds when co-
expressed with Gβ5 [19–24].
Several lines of evidence support an important neurobio-
logical role of Gβ5. Expression analysis revealed strong en-
richment in the brain, particularly in the hippocampus and
striatum [25]. More importantly, Gnb5 knockout mice dis-
play a multitude of neurobehavioral abnormalities [26, 27].
Unless assisted for feeding, these mice die shortly after
birth. Motor delay persists in the early postnatal develop-
mental period and these mice later develop marked hyper-
activity. Interestingly, hyperactivity seen in Gnb5 deficient
mice is paralleled by a number of molecular abnormalities
including higher sensitivity of inhibitory GPCR signaling
and deficits in basal levels, release, and reuptake of dopa-
mine [28, 29]. Since these disturbed processes have been
implicated in the pathogenesis of ADHD in humans, it was
suggested that Gnb5–/– is a good animal model for this dis-
ease [28].
The highly consanguineous nature of the Saudi popu-
lation provides an ideal setting for the discovery of re-
cessive mutations that are too rare to exist biallelically in
outbred populations [30, 31]. We have previously shown
this can greatly accelerate the discovery of novel genes
for various neurodevelopmental disorders [32, 33]. In
this study, we show that an extended consanguineous
family reveals the long sought GNB5-related phenotype
in humans: a neuropsychiatric disorder characterized
by severe impairment in acquisition of speech, hyper-
activity, attention deficits, and motor delay.
Methods
Human participants
All affected family members were evaluated by a certi-
fied pediatric neurologist. The diagnosis of ADHD was
based on established DSM IV criteria. Intelligence was
evaluated using the Wechsler Intelligence Scale for Chil-
dren (WISC) whenever possible. Affected and available
unaffected family members were recruited after signing
a written informed consent form as part of an IRB-
approved research protocol (KFSHRC RAC#2121053).
Venous blood was collected in EDTA and sodium hep-
arin tubes for DNA extraction and the establishment of
lymphoblastoid cell lines, respectively. All experimental
methods comply with the Helsinki Declaration.
Autozygosity mapping and linkage analysis
Genome-wide single nucleotide polymorphism (SNP)
genotyping was carried out using Axiom SNP Chip Array,
which has >500,000 SNPs, following the manufacturer’s
instructions (Affymetrix). Determination of the entire set
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of autozygous intervals per genome (autozygome) used
AutoSNPa. We used regions of homozygosity (ROH)
>2 Mb in size as surrogates of autozygosity [34]. We then
searched for the critical autozygous interval that harbors
the disease-causing mutation by comparing the autozy-
gome of affected and unaffected members to identify
autozygous intervals that are exclusively shared by the af-
fected members as described before [35]. Linkage analysis
was performed using the EasyLINKAGE software. We
used a fully penetrant autosomal recessive disease model
and assumed homozygosity for the disease-causing muta-
tion based on a shared ancestor.
Exome sequencing
Exome capture was performed using TruSeq Exome En-
richment kit (Illumina) following the manufacturer’s
protocol. Samples were prepared as an Illumina sequen-
cing library, and in the second step, the sequencing li-
braries were enriched for the desired target using the
Illumina Exome Enrichment protocol. The captured li-
braries were sequenced using an Illumina HiSeq 2500
Sequencer to an average read depth of target regions of
81.8X. The reads were mapped against UCSC hg19 by
BWA. The SNVs and indels were detected by SAM-
TOOLS. WES data were filtered by only considering
homozygous variants within the critical autozygous
interval, with a MAF <0.001 (as determined by ExAC
and 2379 in-house Saudi exomes) [36]. We assessed po-
tential pathogenicity of missense variants based on Poly-
Phen, SIFT, and CADD.
Complementary DNA constructs
Plasmid encoding the Flag-tagged, long isoform of the
D2 dopamine receptor was a gift from A. Kovoor (Uni-
versity of Rhode Island). pCMV5 plasmids encoding
GαoA were gifts from H. Itoh (Nara Institute of Science
and Technology, Japan). Plasmids encoding Venus 156-
239-Gβ1 and Venus 1-155-Gγ2 were gifts from N. Lam-
bert (Georgia Regents University) [37]. Plasmids encod-
ing RGS9-2, Gβ5, R7BP, and masGRK3ct-Nluc were
previously described [38, 39]. Of the two known splice
isoforms, we chose to study Gβ5S (NM_006578) for its
ubiquitous expression in the nervous system and the
lack of the other isoform, Gβ5L, in the brain.
Real-time monitoring of G protein signaling by fast
kinetic bioluminescence resonance energy transfer assay
Agonist-dependent cellular measurements of bio-
luminescence resonance energy transfer (BRET) be-
tween masGRK3ct-Nluc and Venus-tagged Gβγ were
performed to visualize the action of G protein signaling in
living cells as previously described with slight modifica-
tions [39]. HEK293T/17 was transfected with Lipofecta-
mine LTX (12 μL per dish) and PLUS (7.5 μL per 6-cm
dish) reagents. Dopamine D2 receptor, GαoA, Venus-156-
239-Gβ1, Venus-1-155-Gγ2, masGRK3ct-Nluc, RGS9-2,
Gβ5, and R7BP constructs (total 7.5 μg) were used at a
1:2:1:1:1:1:0.5:0.5:0.5 ratio (ratio 1 = 0.42 μg of plasmid
DNA). BRET measurements were made with a microplate
reader (POLARstar Omega; BMG Labtech) equipped with
two emission photomultiplier tubes, allowing us to detect
two emissions simultaneously with resolution of 20 ms for
every data point. All measurements were performed at
room temperature. The BRET signal is determined by cal-
culating the ration of the light emitted by the Venus-Gβ1γ2
(535 nm with a 30-nm band path width) over the light
emitted by the masGRK3ct-Nluc (475 nm with a 30-nm
band path width). The average baseline value recorded be-
fore agonist stimulation was subtracted from BRET signal
values and the resulting difference (ΔBRET ratio) was plot-
ted as traces. The rate constant (1/τ) of deactivation phase
were obtained by fitting a single exponential function to the
traces with Clampfit ver. 10.3 software (Molecular Devices).
kGAP rate constants were determined by subtracting the
basal deactivation rate constant (kapp) from the deactivation
rate constant measured in the presence of exogenous
RGS9-2/Gβ5 dimer or RGS9-2/Gβ5/R7BP trimer. Obtained
kGAP rate constants were used to quantify GAP activity of
RGS9-2 complexes.
Immunoblotting
Western blot was carried out to check for the stability of
GNB5 protein in patient lymphoblasts compared to con-
trol lymphoblasts, using Anti-GNB5(ab185214-Abcam).
Briefly, protein was extracted using RIPA buffer (SIGMA)
and Halt protease inhibitor cocktail (Thermo-Fisher Scien-
tific), followed by centrifugation at 14,000 g at 4 °C for
15 min. Protein obtained in the supernatants was sepa-
rated by electrophoresis on 4–12 % gradient Tris–gly-
cine gels (Invitrogen) and transferred onto polyvinylidene
difluoride membrane (Invitrogen), followed by blocking in
1× PBS with 5 % casein and 0.1 % Tween-20, incubation
with primary antibody, and finally incubation with horse-
radish peroxidase-conjugated IGg secondary antibody.
SuperSignal chemiluminescent substrate kit (Pierce) was
applied to detect the level of protein expression. Reduc-
tion in the protein level was quantified using ImageJ and
compared across three independent immunoblots. Im-
munoblotting of transfected cells were performed as pre-
viously reported [22]. To ensure pseudo-linearity of the
signal several film exposures were evaluated and non-
saturating blots were chosen for the analysis.
Results
Identification of a novel autosomal recessive
neuropsychiatric disorder
Through our ongoing effort to identify Mendelian forms
of neuropsychiatric disorders in children, we encountered
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an extended consanguineous Saudi family with multiple
members who share the core feature of severe expressive
language delay (Additional file 1: Table S1). The five af-
fected members represent three different sibships (Fig. 1).
In the first sibship, the index (V:1) is a 10-year-old girl
who presented to pediatric neurology with severe expres-
sive and receptive language delay, marked hyperactivity,
and school performance issues despite having a normal
IQ. She was diagnosed with ADHD according to the DSM
IV criteria. Her younger 9-year-old sister (V:2) also had se-
vere expressive and receptive language delay, and although
she had no hyperactivity, she met the DSM IV criteria for
inattentive type ADHD. Like her sister, she had normal
cognitive development. The youngest 3-year-old sister
(V:3) was too young to assess for ADHD but, like her
other two sisters, had severe language delay. Their first
cousin is a 5-year-old girl (IV:1) who initially presented
with motor delay and hypotonia but was later found to
have severely delayed language development but normal
IQ. A distant cousin (IV:6, 9 years old) was not available
for formal evaluation but available reports from a different
institution showed ADHD diagnosis, severely delayed lan-
guage acquisition, and mild motor delay.
A novel neuropsychiatric syndrome is linked to a novel
variant in GNB5
The pedigree structure was highly suggestive of an auto-
somal recessive inheritance (the apparent female predomin-
ance was likely reflective of the mostly female offspring in
the three nuclear families). Therefore, we proceeded with
autozygome analysis and identified a single autozygous
interval that was exclusively shared by the five affected
members IV:1, IV:6, V:1, V:2, and V:3 (Fig. 1). Under the hy-
pothesis that the phenotype observed in this family is
caused by homozygosity for a pathogenic mutation within
an ancestral haplotype, we proceeded with linkage analysis
and the result was fully concordant with autozygosity map-
ping in that the same critical interval was identified and a
significant LOD score of ~4 was obtained (Fig. 1). We then
exome sequenced the index and despite full coverage (>10
reads) of all exons of 104 genes in the critical interval, only
one novel homozygous variant was identified therein:
Fig. 1 A novel neuropsychiatric disorder is linked to GNB5 mutation. a Pedigree of the study family. b Ideogram showing a single autozygous
interval on chr15 (47,051,884-57,799,765, demarcated by SNPs rs11854077 and rs1280355) that is exclusively shared by the affected members.
c Genome-wide linkage analysis shows a single linkage peak on chr15 with LOD ~4 that corresponds to the single autozygous interval shown in
(b). A screenshot from the UCSC Genome Browser is shown to highlight the gene content of the linkage peak (GNB5 is boxed in red). d Schematic
of GNB5 (transcript NM_ 006578) with the sequence chromatogram of the mutation shown on top. e Schematic of Gβ5 and the location of the
missense mutation indicated. f Strong cross-species conservation of the Ser81 residue denoted with a red asterisk (black asterisks in the bottom
denote highly conserved residues)
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GNB5: NM_006578.3:c.242C >T:p.(S81L). This variant is
absent in 2379 Saudi exomes and in the 1000 Genomes,
and is present at a very low frequency in ExAC (6 out of
121,000 alleles with MAF of 4.959e-05, 0 homozygotes). It
fully segregated with the syndrome in the family such that
all affected members were homozygous, parents were het-
erozygous, while unaffected siblings were either heterozy-
gous or homozygous for the normal allele (Fig. 1). The
identified amino acid substitution maps to the first WD40
repeat of the seven-propeller Gβ5 fold within highly con-
served region unique to this repeat (Fig. 1d).
S81L Gβ5 has reduced capacity to deactivate G protein
signaling initiated by dopamine receptors
Given the central role of dopamine in a variety of neuro-
psychiatric conditions and documented role of R7 RGS-
Gβ5 complexes in controlling signaling by the D2 dopa-
mine receptors (D2R) [28], we have next evaluated the
functional impact of S81L mutation in Gβ5 on termination
of D2R responses, using a representative member of the R7
family, RGS9-2. We used optical means to record activation
and deactivation of G protein Go by D2R in living cells by
monitoring changes in BRET signal caused by dissociation
of Go heterotrimer (Fig. 2a). In this assay, the addition of
dopamine resulted in a rapid increase in BRET signal,
which returns to the baseline upon the addition of the an-
tagonist haloperidol (Fig. 2b). The speed of this termination
phase is accelerated by RGS9, which in turn depends on
Gβ5 for its activity (Fig. 2c). Thus, the functional activity of
Gβ5 was determined by its ability to speed up D2R deacti-
vation upon the addition of haloperidol in the presence of
RGS9-2. Indeed, expressing wild-type Gβ5 substantially ac-
celerated response termination (Fig. 2c, green versus blue
traces in the left graph). In contrast, the response offset kin-
etics was substantially slower in the presence of S81L
(Fig. 2c, blue versus red traces in the left graph). Calculating
the catalytic efficiency of the reaction by single exponential
analysis revealed significantly weaker activity of RGS com-
plexes containing mutant Gβ5 (Fig. 2d). In addition to Gβ5,
R7 RGS complexes in vivo contain membrane anchoring
subunit R7BP, which further augments their catalytic activ-
ity and requires Gβ5for function [38]. Therefore, we next
determined the effect of Gβ5 mutation in the presence of
R7BP. Again, the addition of WT Gβ5 dramatically facili-
tated the activity of RGS9-2, but this effect was very modest
when S81L Gβ5 was used instead. Therefore, we conclude
that S81L results in severe but incomplete loss of function,
detrimentally affecting the ability of R7 RGS proteins to de-
activate D2R-mediated signaling.
S81L mutation compromises Gβ5 stability and reduces its
ability to augment RGS expression
We next sought to determine the mechanisms by which
S81L mutation affects Gβ5 function. In silico prediction
suggests that the S81L variant likely has deleterious
structural effects with three algorithms concurring on
very high pathogenicity scores (1.0 on PolyPhen, 0.0 on
SIFT, and 34 on CADD). To obtain structural insights
into the impact of the S81L mutation on Gβ5 at the
atomic level, we modeled the consequences of this sub-
stitution using crystal structure of RGS9-Gβ5 complex
(Fig. 3a, b) [40]. S81 is buried inside the β-strand S2β2
of WD1 repeat close to central axis of β-propeller fold.
The S81 is involved in side-chain–main-chain type of
hydrogen bond with V108 (Fig. 3c) and such interactions
are known to be crucial for maintaining stable structure
of the protein [41, 42]. Our modeling suggests that sub-
stituting Ser81 with hydrophobic leucine would abolish
hydrogen bond formation with V108 and bulkier side
chain of leucine at this position would not fit into the
tightly packed antiparallel β-sheet of WD1 repeat resulting
in a steric clash with neighboring residues (V87 on WD1;
V108, C111, and C122 on WD2 (Fig. 3c). Thus, S81L sub-
stitution is predicted to compromise Gβ5 folding and/or
stability. To test these predictions, we analyzed the expres-
sion of Gβ5 in patient-derived lymphoblasts by immuno-
blotting. Indeed, we detected a modest but consistent
reduction of Gβ5 protein levels in the two available lym-
phoblastoid lines derived from affected patients compared
to healthy controls (Fig. 3d, e). In order to rule out the
possibility that the apparent reduction in GNB5 protein
may have originated at the transcript level, qRT-PCR
using patient and control RNA revealed equivalent levels
of GNB5 transcripts (Fig. 3).
To further characterize the effects of the mutation on
the expression of Gβ5, we heterologously expressed Gβ5
constructs in HEK293T cells and determined its levels by
immunoblotting. Similar to results with lymphoblastoid
cells, we observed that S81L Gβ5 mutant had lower ex-
pression levels relative to wild-type protein (Fig. 3f). Fur-
thermore, S81L Gβ5 had a reduced capacity to augment
the expression of RGS9-2 both in the absence or presence
of R7BP, suggesting detrimental effect of the mutation on
the folding or stability of the R7 RGS complexes.
Discussion
The family we present in this study provides a unique op-
portunity to observe the phenotypic consequence of Gβ5
deficiency in humans. GNB5 knockdown in C. elegans re-
sults in increased locomotor activity [43]. Knockout of the
murine orthologue results in severe hyperactivity and ab-
normal motor coordination, findings that made us suggest
that GNB5 is a candidate gene for ADHD in humans [28].
ADHD is an extremely common psychiatric disorder that
affects 5 % of school-age children, although some surveys
estimate the prevalence to be >11 % [44]. Despite its high
prevalence and strong heritability, very little is known
about its genetics. Like most other complex disorders,
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information on the genetics of ADHD comes from linkage
analysis of families with strong familial aggregation, candi-
date gene case-control as well as genome-wide association
studies (GWAS) [45, 46]. Interestingly, Mendelian forms,
which have been identified for many other complex disor-
ders, have not been reported for ADHD to date. Perhaps
more surprising is that, unlike other complex disorders,
recent advances in sequencing technology have only rarely
been exploited in ADHD to identify rare variants that
evade detection by traditional GWAS [47].
Motor delay, a consistent feature in Gnb5 KO mouse,
was also variably observed in patients we describe in this
study. Similarly, hyperactivity, another prominent pheno-
type in Gnb5 KO mouse, was only present at reduced
Fig. 2 Effect of S81L mutation on GAP activity of RGS9-2 complex. a Schematic of the assay design. Stimulation of dopamine D2 receptor (D2R)
by dopamine results in the dissociation of GαoA from the heterotrimer. Released Venus-tagged Gβγ subunits become available for interaction
with Nluc-tagged GRK3ct reporter, producing the BRET signal, which is determined by the change in the emission ratio at 535 nm and 480 nm.
RGS9-2/Gβ5 complexes exert GTPase Activating Protein (GAP) activity and accelerate deactivation of G proteins. b Representative BRET response
of cells reconstituted D2R-GoA signaling. Responses to sequential application of dopamine (100 μM) and haloperidol (100 μM) were recorded.
Data are means of six replicates. c Trace lines represent the deactivation phase of D2R-GoA signaling after haloperidol application to cells transfected
with different condition (left without R7BP and right with R7BP). Data are means of six replicates. d kGAP rate constants were calculated as an enzymatic
activity of RGS9-2 complexes (for further details, see “Methods”) and plotted as a bar graph. The same color code was used in panel c and d. A single
asterisk (*) indicates P <0.0001. One-way ANOVA followed by Dunett’s post-hoc test was conducted with GraphPad Prism Ver. 6. Results shown are
representative of two independent experiments each performed with six replicates. Values represent means ± SEM
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penetrance in the patients we describe with GNB5 muta-
tion. This could be explained on the basis that these pa-
tients have partial whereas Gnb5 KO mice have complete
loss of function. Expectation is that the severity may cor-
relate with severity of Gβ5 disruption and other genetic
factors may contribute to how much Gβ5 destabilization
the particular mutation would cause, e.g. strength of fold-
ing machinery, or lower tone of dopamine signaling in
general in unaffected subjects. This suggests that even in
this Mendelian form of ADHD, modifiers may play an im-
portant role in defining the final phenotype.
Our previously published detailed analysis of the sig-
naling perturbation in the brains of Gnb5 KO mice sug-
gested a model where increased availability of dopamine
is not accompanied by a reciprocal increase in serotonin
and that this imbalance may underlie the pathogenesis
of hyperactivity in these mice [28]. This model is further
supported by our finding that psychostimulant drugs that
increased the availability of dopamine failed to treat hyper-
activity symptoms whereas drugs that increased the avail-
ability of serotonin resulted in a dramatic response [28].
The implication of this on the choice of therapy of GNB5-
related ADHD remains to be seen.
G protein–gated inwardly rectifying K+ (GIRK/Kir3)
channels play an important role in synaptic plasticity
and behavior [48, 49]. We have previously shown that
Gβ5 co-immunoprecipitates with the GIRK2 and GIRK3
neuronal subunits of GIRK and mediates the formation
Fig. 3 Effect of S81L mutation on protein expression of Gβ5 and RGS9-2 complex. a Cartoon representation of RGS9-Gβ5 complex crystal structure
(PDB ID:2PBI) with S81L mutation shown in the red sphere. RGS9 and Gβ5 are shown in gray and cyan, respectively. b Cartoon representation of
Gβ5 alone (PDB ID:2PBI) with S81 mutation shown in the red sphere. Residue S81 is present on β-strand S2β2 of WD1 repeat. WD1 and the neighboring
WD2 repeats are represented in blue and orange, respectively. c The hydrogen bond formation of side chain of S81 (red) with backbone of V108 (orange)
is shown as a dotted black line. The substituted residue L81 (green stick) will not be able to form a hydrogen bond; instead its bulkier side chain will have
steric clashes with neighboring amino acids (V87, V108, C111, and C122 represented in stick). All structural representations are made using
PyMOL software https://www.pymol.org. d Summary of three qRT-PCR experiments (each performed in triplicates) using patient and control LCL to
determine the relative abundance of GNB5 in patient vs. controls showing no significant difference (two-tailed t-test p value 0.67). e, f Western
blot analysis of GNB5 expression in patient lymphoblastoid cells compared to normal control. g Immunoblot analysis of protein expression in
HEK293T/17 cells. RGS9-2, Gβ5, and R7BP were expressed in different combinations. The proteins extracted from the transfected cells used in
BRET assay were subjected to immunoblot analysis using the indicated specific antibodies. Anti-GAPDH antibody was used as a loading
control. Representative experiment out of three independent evaluations is shown
Shamseldin et al. Genome Biology  (2016) 17:195 Page 7 of 9
of GIRK-RGS complex [29]. In hippocampal neurons
from Gnb5–/– mice, deactivation of GIRK signaling after
GABA binding was significantly slower than in the wild-
type counterpart. Furthermore, hippocampal CA1 pyram-
idal neurons from Gnb5–/– mice showed altered evoked
inhibitory postsynaptic currents, an important inhibitory
signaling in the nervous system [29]. These findings are
likely relevant to the GNB5-related human phenotype be-
cause the use of the GABA agonist baclofen was found to
induce marked reduction in hyperactivity in Gnb5–/– mice
[29]. In addition, abnormal synaptic transmission in hip-
pocampal neurons may contribute to the abnormality in
expressive language we observe in all five patients with
GNB5 mutation given the role of hippocampal declarative
memory system in language development [50]. We also
note that mutations in KCNJ6, which encode GIRK2, are
known to cause a severe neurocognitive phenotype in
humans [51]. Finally, it is worth highlighting the role of
Gβ5 in regulating adenylate cyclase signaling in the stri-
atum, a major player in motor coordination, as a potential
mechanism to explain delayed fine motor coordination
observed in patients with GNB5 mutation [52–54]. Given
the obligate nature of Gβ5 association with members of
the R7 RGS family and characteristic sensitization of
GPCR signaling observed upon Gβ5 elimination, we think
that loss of the R7 RGS function underlies the majority of
phenotypes in both humans and mice with disabled Gβ5.
Consistent with this idea, we report that S81L mutation in
Gβ5 detrimentally affects function of a representative
member of the R7 RGS family, RGS9-2. Yet we expect
that mutations in Gβ5 would similarly affect all members
of the R7 family, leading to a global reduction in RGS ac-
tivity in multiple neuronal circuits across the brain. We
should note, however, that at present we cannot rule out
the RGS-independent effects associated with the Gβ5
dysfunction, which may be interesting to re-visit if and
when additional molecular reactions involving Gβ5 are
discovered.
Conclusions
In conclusion, we suggest that GNB5 mutation in human
results in an autosomal recessive neuropsychiatric dis-
order that is characterized by severe language delay, fine
motor delay, and incompletely penetrant ADHD pheno-
type. It will be of interest to examine the contribution of
rare variants in GNB5 in future exome/genome sequen-
cing studies of patients with ADHD, especially those with
severe speech delay that is out of proportion to their IQ.
Additional file
Additional file 1: Table S1. Clinical summary of the study patients.
Clinical characteristics of the five patients included in this study with
homozygous GNB5 mutation. (DOCX 14 kb)
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